Acute respiratory distress syndrome (ARDS) is a refractory hypoxemic respiratory failure with bilateral lung infiltrates, in the absence of left atrial hypertension or evidence of volume overload [1, 2].
One of major pathophysiologic mechanisms in the early phase of ARDS is known to be endothelial injury and alveolar epithelial damage from proinflammatory cascade [7] , leading to the process of proliferation and fibrosis [8] .
Inflammatory biomarkers such as tumor necrosis factoralpha, interleukin 6, platelet activating factor are known to involve in ARDS pathogenesis [9] [10] [11] . In the advanced stage, activated alveolar fibrocytes, fibroblasts and myofibroblasts may drive fibroproliferation, although the process remains unclear [12] . These inflammatory cytokines and increased pulmonary fibrosis predict unfavorable outcome and higher mortality [13, 14] . Therefore, the anti-inflammatory therapy or prevention of pulmonary fibrosis in ARDS could be targets of therapy to improve survival.
Angiotensin II exerts proinflammatory responses through activating nuclear factor-κB in monocytes [15] .
The renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) reduces nuclear factor-κB activation and lipopolysaccharide induced lung neutrophil recruitment [15] [16] [17] . Rats with acute lung injury showed lower lung injury score or alveolar collagen deposit when treated with captopril and they suggested inhibition of ACE could offer protective effects on acute lung injury [18] [19] [20] [21] . The mechanism is supposed that captopril attenuates lung fibrosis by abrogating apoptosis in lung epithelial cells. ACE inhibitor is also well known to have a protective effect against fibrosis and remodeling, notably in the liver, kidneys and heart [22] [23] [24] . However, there was little evidence that ACE inhibitor played a protective role in human ARDS.
We hypothesized that ACE inhibitor could provide beneficial effects for ARDS patients by protecting them from prolonged inflammation and fibrosis. Therefore, we conducted this study to determine whether there is a difference in clinical outcomes including mortality rates in ARDS patients according to the use of ACE inhibitor or ARB.
Materials and Methods

1) Patients population
We retrospectively reviewed the medical records and radiographs of patients admitted to the medical intensive care unit (MICU) at a tertiary care hospital for mechanical ventilation support between January 2005 and December 2010. Eligibility criteria were that patients were:
(1) over 20 years of age, and (2) fulfilled the Berlin defi- ≥5 cmH 2 O) [25] . We excluded patients who were not intubated within 24 hours of ICU transfer or did not stay in the ICU for more than 48 hours following admission.
Patients who were intubated and transferred from outside were also excluded.
2) Study design and data collection
Patients were classified into two groups according to whether or not they took ACE inhibitor/ARB after ICU admission (RAS inhibitor group and non-RAS inhibitor group, respectively). The primary outcome was ICU mortality, and second- 
Results
We Of the 182 patients, 134 (74%) were male and the mean age was 64.1 ± 13.7 years. Thirty-seven patients received ACE inhibitor and ARB during their ICU stay. Table 1 presents the patients' demographic characteristics and The average PEEP levels were about 6.9 cmH 2 O in both groups (P = 0.681). Tidal volumes were also similar, those values were 7.4 ± 1.9 ml/kg and 7.5 ± 1.9 ml/kg, and mechanical ventilator parameters were similar between two groups in the propensity score matched cohort.
About 60% of the patients in the RAS inhibitor group had taken ACE inhibitor or ARB within 1 month before MICU admission (Table 2 ). In the RAS inhibitor group, 10 patients had been given ACE inhibitor and 27 patients were given ARB.
For the patients receiving ACE inhibitor/ARB, ICU mortality was 45.9% (17 of 37 patients), which was lower than the 58.9% mortality rate of patients without medication, though not significantly (P = 0.166) ( Table 3 ). Inhospital mortality was also higher in the non-RAS inhibitor group and the day 28 mortality in non-RAS inhibitor group was almost twice as high without statistical significance (18.9% vs. 35.2%, P = 0.058). In the propensity score matched cohort, in hospital mortality at day 28 was also higher in non-RAS inhibitor group (29.4%) than RAS inhibitor group (8.8%, P = 0.031). However, other parameters of outcome including in hospital mortality at day 90 showed no significant differences between two groups.
ICU-free day at 28 days were about 5 days, similar in both groups (P = 0.822). ICU-free day at 90 days was longer in RAS inhibitor group (mean, 34.2 days) than non-RAS inhibitor group (mean, 29.4 days; P = 0.481).
There was also no significant difference in hospital-free day at 90 days and ventilator-free day at 28 days, between two groups.
The Kaplan-Meier estimate of survival showed a higher mortality rate in non-RAS inhibitor patients (P < 0.001) (Figure 2 ). Survival analysis after adjustment for propensity score showed similar results in each group (P = 0.002).
Discussion
Although many studies have been conducted to establish pharmacologic management of patients with ARDS, there is no proven pharmacologic therapy to improve the survival and prognosis of ARDS patients [26] . Clinical trials using well-known anti-inflammatory agents, in- Interestingly, several studies conducted to support antiinflammatory effect of ACE inhibitor in vascular disease [31] [32] [33] and also showed protective effect against pneumonia [34, 35] . In addition, some animal models have revealed that administration of ACE inhibitor or ARB inhibits fibrosis in the kidneys, heart and liver [36] [37] [38] [39] . We therefore tried to evaluate the effect of anti-inflammatory and antifibrotic properties of ACE inhibitor and ARB on outcomes in patients with ARDS.
In this study, radiologic improvement was more frequently detected in the RAS inhibitor group, although cluding fibrosis in RAS inhibitor group. The mortality rates, both in the ICU and in the hospital,
were not different in both groups. The overall mortality rate was high compared to other cohorts, which estimated mortality rates ranged from 28% to 58% [31, 43, 44] .
It might reflect high disease severity considering high APACHE II score and high proportion of cancer patients in our study [45] . Among the patients who died, the duration of ICU stay was longer (P = 0.001) in the RAS inhibitor group than in the non-RAS inhibitor group, which might explain the lower 28-day mortality rates. Survival analysis showed significantly better survival rates in the RAS inhibitor group. We adjusted confounding factors, including disease severity, using the propensity score, and found the same results as above. The likelihood of survival of patients with ARDS could be improved by the administration of RAS inhibitor.
This study has several limitations. First, ARDS is a complicated syndrome, and it is difficult to distinguish ARDS from other diseases that might cause radiologic abnormality and respiratory failure. However, we did our best to overcome the weakness of the retrospective design. We reviewed all medical records, including echocardiography results, daily body weight changes and vital sign changes, to evaluate volume status. Records of physical examination and assessment by medical attendance were also reviewed to exclude other diseases.
Second, ACE inhibitors or ARB administered to patients did not have uniform component or dosage. However, for the treatment of hypertension, ACE inhibitor and ARB showed similar efficacy in lowering blood pressure [46, 47] . Though the mechanisms of action between ACE inhibitor and ARB are different, there was no relevant difference in clinical outcomes for renal protection [48] .
Further researches are needed to compare efficacy in anti-inflammatory effect. Third, the sample size was relatively small, and a considerable number of patients had many comorbidities. These confounding factors might have influenced the outcome [49] .
In conclusion, in this study we found that ACE inhibitor or ARB may have beneficial effect on ARDS patients.
We need large prospective clinical study to validate this finding.
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